Table 1.
Baseline CD30 | CD30 level at decreased brentuximab vedotin efficacy |
% knockdown | |
---|---|---|---|
NKL | 2.41 | 1.32 | 45% |
Karpas 299 | 5.11 | 2.57 | 50% |
Kem III | 1.67 | 1.14 | 32% |
This table summarizes the absolute amount of baseline CD30 present in each cell line, the amount of CD30 left when brentuximab vedotin efficacy begins to decrease and the percent knockdown that the decrease in CD30 represents. CD30 is measured in ng/µg total cellular protein.